Regulated information - Inside information argenx announces launch of proposed global offering

Regulated information - Inside information

argenx announces launch of proposed global

Breda, the Netherlands / Ghent, Belgium - argenx

(Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based

therapies for the treatment of severe autoimmune diseases and cancer, announced today that it has commenced a global offering of

$500 million (approximately 458.3 million) of ordinary shares, which may be represented by American Depository Shares ("ADSs").

The global offering will be comprised of an offering of ordinary shares represented by ADSs in the United States and certain other

countries outside of the European Economic Area and a simultaneous private placement of ordinary shares in the European Economic

Area. Each of the ADSs represents the right to receive one ordinary share, nominal value of 0.10 per share. The U.S. offering

and the European private placement are expected to close simultaneously.

In addition, argenx intends to grant the underwriters of the

offering a 30-day option to purchase additional ordinary shares (which may be represented by ADSs) in an aggregate amount of up

to 15% of the total number of ordinary shares (including represented by ADSs) proposed to be sold in the offering, on the same

terms and conditions.

argenx's ADSs are currently listed on the Nasdaq Global

Select Market under the symbol "ARGX." and argenx's ordinary shares are currently listed on Euronext Brussels

under the symbol "ARGX.".

J.P. Morgan, Cowen and BofA Securities are acting as joint bookrunning

managers for the offering.

The securities are being offered in the United States pursuant

to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission

("SEC"). A preliminary prospectus supplement relating to the securities being offered in the United States will be

filed with the SEC and will be available on the SEC's website at www.sec.gov.

When available, copies of the preliminary prospectus supplement

and the accompanying prospectus relating to these securities being offered in the United States may be obtained for free from J.P.

Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866)

803-9204, or by email at prospectus-eq_fi@jpmchase.com; from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long

Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com, or by telephone

at (833) 297-2926; or from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, North Carolina 28255-0001,

Attn: Prospectus Department, or by email at dg.prospectus_requests@baml.com.

A request for the admission to listing

and trading of the ordinary shares (including the ordinary shares underlying the ADSs) on the regulated market of Euronext Brussels

will be made following pricing of the offering. A prospectus for the listing of the ordinary shares on Euronext Brussels consisting

of a universal registration document dated 31 March 2020, an amendment to the aforementioned universal registration document,

a securities note and a summary (together, the "Listing Prospectus") will be filed with the Dutch regulator

(Stichting Autoriteit Financi le Markten) (the "AFM") for approval and passporting to Belgium in accordance

with article 25 of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to

be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC

(as amended, the "Prospectus Regulation"). Upon approval, the Listing Prospectus together with a Dutch translation

of the summary will be made available on the website of argenx (www.argenx.com) and copies may be obtained for free from

argenx upon request at info@argenx.com or by telephone at (32) 9 310 34 19.

This press release is for information purposes only and does

not constitute, and should not be construed as, an offer to sell or the solicitation of an offer to buy or subscribe to any securities,

nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale is not permitted or to

any person or entity to whom it is unlawful to make such offer, solicitation or sale. Reference is also made to the restrictions

set out in "Important information" below. This press release is not for publication or distribution, directly or indirectly,

in or into any state or jurisdiction into which doing so would be unlawful or where a prior registration or approval is required

argenx is a global immunology company developing antibody-based

medicines for patients suffering from severe autoimmune diseases and cancer. By translating immunology breakthroughs into innovative

drug candidates, argenx is building a world-class portfolio of first-in-class antibodies in both early and late clinical-stages

of development. argenx is evaluating efgartigimod in multiple serious autoimmune indications and cusatuzumab in hematological malignancies

in collaboration with Janssen, along with advancing earlier stage assets within its therapeutic franchises.

For further information, please contact:

Joke Comijn, Director Corporate Communications & Investor

Beth DelGiacco, Vice President, Investor Relations (US)

Forward-looking Statements

The contents of this announcement include statements that

are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the

use of forward-looking terminology, including the terms "believes," "estimates," "anticipates,"

"expects," "intends," "may," "will," or "should," and include statements

argenx makes concerning the completion, timing and size of the proposed global offering and its expectations with respect to granting

the underwriters a 30-day option to purchase additional ordinary shares (which may be represented by ADSs). By their nature,

forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are

not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking

statements as a result of various important factors, including the impact that the COVID-19 pandemic and resulting economic conditions

will have on argenx's operations and business; argenx's expectations regarding the inherent uncertainties associated

with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements;

argenx's reliance on collaborations with third parties; estimating the commercial potential of argenx's product candidates;

argenx's ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx's

limited operating history; and argenx's ability to obtain additional funding for operations and to complete the development

and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can

be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most

recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC

and will also be contained in the Listing Prospectus filed by argenx with the AFM in respect of the listing of the ordinary shares

on Euronext Brussels. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking

statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation

to publicly update or revise the information in this press release, including any forward-looking statements, except as may be

Important information

This announcement is not an advertisement and not a prospectus

within the meaning of the Prospectus Regulation and has not been approved by the AFM or the Belgian Financial Services and Markets

Authority (Autoriteit Financi le Diensten en Markten) or any other European Supervisory Authority.

No public offering will be made and no one has taken any

action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where

any such action is required, including in the European Economic Area. In the European Economic Area, the offering to which this

press release relates will only be available to, and will be engaged in only with, qualified investors within the meaning of the

Prospectus Regulation.

European Economic Area:

No action has been or will be taken to offer the ordinary

shares to a retail investor established in the European Economic Area as part of the global offering. For the purposes of this

In addition, in the United Kingdom, the transaction to which

this press release relates will only be available to, and will be engaged in only with, investment professionals falling within

Article 19(5) of the Financial Services and Markets Act (Financial Promotion) Order 2005, as amended (the Order), persons

falling within Article 49(2)(a) to (d) of the Order, and other persons to whom this announcement may lawfully be

communicated (all such persons together being referred to as "relevant persons"). The securities referred to herein

are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will

be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication

or any of its contents.

This press release is not an approved prospectus by the Financial